cardiac catheterization
Procedurecardiac catheterizations will be clinically indicated and the study will collect this clinical data.
NCT Number: NCT03564522
This study looks to develop a multi-scale computational model of Pulmonary Hypertension, this clinical model will be calibrated using longitudinal, retrospectively and prospectively acquired human clinical data.
Looking for future studies?
Notify Me6 year–25 year
All sexes
Observational
Mott Children's Hospital University of Michigan, Ann Arbor, Michigan, United States
Pulmonary hypertension (PH) is a complex disorder associated with elevated pulmonary arterial pressure. Unlike systemic hypertension, PH is difficult to detect in routine physical examinations and the current gold standard for diagnosing PH is through invasive right heart catheterization. Prolonged PH results in functional, structural and anatomical changes in the right ventricle (RV), large pulmonary arteries, and the pulmonary micro-circulation that ultimately lead to decompensated RV failure and death. Unlike in systemic hypertension, for which patients have effective pharmacological management of blood pressure for decades, PH prognosis remains poor with 15% mortality within 1 year on modern therapy. Our current understanding of PH has largely been obtained through animal models and clinical studies. However, surgical banding or chronic hypoxia animal models do not fully reproduce the etiology of human PH, whereas invasive clinical measurements of pulmonary vascular resistance (PVR), stiffness and ventricular elastance provide limited insight into disease progression. Therefore, there is a pressing need to develop a multi-scale (MS) computational model that can couple the short term (e.g. hemodynamics) and long-term G&R interactions between the RV and the pulmonary circulation.
The overall goals of this project are to use the framework to (1) describe the time course of the biomechanical alterations and (2) identify the key mechanical culprits associated with PH-induced heart failure so that clinical interventions can be targeted against them.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
cardiac catheterizations will be clinically indicated and the study will collect this clinical data.
If clinically indicated, the study will collect data from MRIs.
Time frame: 1 hour
Modeling framework will be validated using 3D volumetric data (mL/m2) gathered via cardiac MRI
Time frame: 1 hour
Modeling framework will be validated using cardiopulmonary flow (mL/beat) gathered via cardiac MRI
Time frame: 2 hours
Modeling framework will be validated using pressures (mmHg) gathered via cardiac catheterization
University of Michigan
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06671171
Arterial Occlusive Diseases, Arteriosclerosis
Hong Kong
View Trial DetailsNCT01287026
Cardiovascular Abnormalities, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07663799
Apple Watch, Cardiovascular Abnormalities
Hong Kong
View Trial DetailsNCT03149341
Cardiovascular Abnormalities, Cardiovascular Diseases
Palo Alto, California, United States
View Trial Details